Showing results (111-120 of 166) with videos related to
Sort By:
Pageof 17
Journal of Gastroenterology and Hepatology|January 6, 2025
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk ModelsTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Liver Cancer|August 21, 2023
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter AnalysisAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Journal of Gastroenterology and Hepatology|May 26, 2023
Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinomaToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 28, 2022
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practiceTakaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 12, 2023
Geriatric nutritional risk index as an easy-to-use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumabAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Alimentary Pharmacology & Therapeutics|September 5, 2024
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patientsTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.Cancer Medicine|January 22, 2025
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular CarcinomaAtsushi Naganuma, Satoru Kakizaki, Atsushi Hiraoka, et al.Cancer Medicine|June 6, 2022
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinibAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Oncology|June 12, 2023
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve FunctionAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.Oncology|August 8, 2023
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical SettingsHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.Pageof 17